Predicting T cell recognition of MHC class I restricted neoepitopes.

ABSTRACT: Epitopes that arise from a somatic mutation, also called neoepitopes, are now known to play a key role in cancer immunology and immunotherapy. Recent advances in high-throughput sequencing have made it possible to identify all mutations and thereby all potential neoepitope candidates in an individual cancer. However, most of these neoepitope candidates are not recognized by T cells of cancer patients when tested in vivo or in vitro, meaning they are not immunogenic. Especially in patients with a high mutational load, usually hundreds of potential neoepitopes are detected, highlighting the need to further narrow down this candidate list. In our study, we assembled a dataset of known, naturally processed, immunogenic neoepitopes to dissect the properties that make these neoepitopes immunogen

SUBMITTER: Kosaloglu-Yalcın Z 

PROVIDER: S-EPMC6204999 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature